Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity (Q46726161)

18 June 2018

title

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity (English)

1 reference

18 June 2018

1 reference

1 reference

1 reference

1

1 reference

18 June 2018

Everett E Vokes

16

object named as

Everett E Vokes

1 reference

18 June 2018

18

Mark J Ratain

1 reference

18 June 2018

Michael A. Carducci

17

object named as

Michael A Carducci

1 reference

18 June 2018

author name string

Apurva Desai

3

1 reference

18 June 2018

Theodore Karrison

4

1 reference

18 June 2018

Xuemin Jiang

5

1 reference

18 June 2018

Linda Janisch

6

1 reference

18 June 2018

Soma Das

7

1 reference

18 June 2018

Jacqueline Ramirez

8

1 reference

18 June 2018

Balasubramanian Poonkuzhali

9

1 reference

18 June 2018

Erin Schuetz

10

1 reference

18 June 2018

Donna Lee Fackenthal

11

1 reference

18 June 2018

Peixian Chen

12

1 reference

18 June 2018

Deborah K Armstrong

13

1 reference

18 June 2018

Julie R Brahmer

14

1 reference

18 June 2018

Gini F Fleming

15

1 reference

18 June 2018

language of work or name

English

0 references

publication date

1 March 2008

1 reference

18 June 2018

Journal of Clinical Oncology

published in

1 reference

18 June 2018

volume

26

1 reference

18 June 2018

issue

7

1 reference

18 June 2018

page(s)

1119-1127

1 reference

18 June 2018

Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

The pharmacogenetics research network: from SNP discovery to clinical drug response.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Erlotinib in lung cancer - molecular and clinical predictors of outcome

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Genetics of the variable expression of CYP3A in humans

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Cloning of a variant epidermal growth factor receptor

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5846189

The genetic determinants of the CYP3A5 polymorphism

15 August 2018

1 reference

12 December 2020

Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression

1 reference

12 December 2020

Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

1 reference

12 December 2020

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

1 reference

12 December 2020

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

1 reference

12 December 2020

Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region

1 reference

12 December 2020

Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2007.13.1128

1 reference

18 June 2018

PMC publication ID

5846189

1 reference

18 June 2018

PubMed publication ID

18309947

1 reference

18 June 2018